YOUR BUSINESS AUTHORITY
Springfield, MO
Celgene Corp. penned a deal to acquire Juno Therapeutics Inc. for about $9 billion.
Celgene would gain Juno's class of therapies known as CAR-T, which use the body's own immune system to battle cancer.
The acquisition is reportedly one of Celgene's largest deals ever.
Read more from Bloomberg.
Project work in Springfield corridor will continue into 2031.